Analysts Anticipate Agenus Inc. (NASDAQ:AGEN) to Announce -$0.27 EPS

Wall Street brokerages forecast that Agenus Inc. (NASDAQ:AGEN – Get Rating) will post earnings per share (EPS) of ($0.27) for the current quarter, according to Zacks. Three analysts have provided estimates for Agenus’ earnings. The lowest EPS estimate is ($0.30) and the highest is ($0.23). Agenus posted earnings of ($0.37) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 27%. The firm is expected to issue its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Agenus will report full-year earnings of ($1.09) per share for the current year, with EPS estimates ranging from ($1.20) to ($1.01). For the next financial year, analysts expect that the business will post earnings of ($0.83) per share, with EPS estimates ranging from ($1.22) to ($0.52). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Agenus.

Agenus (NASDAQ:AGEN – Get Rating) last announced its quarterly earnings results on Tuesday, May 10th. The biotechnology company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.11. During the same period in the prior year, the firm earned ($0.27) earnings per share.

Several equities research analysts have recently commented on the company. Zacks Investment Research downgraded Agenus from a “hold” rating to a “sell” rating in a report on Friday, March 4th. HC Wainwright increased their price target on Agenus from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, March 2nd. StockNews.com initiated coverage on Agenus in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. Finally, B. Riley dropped their price target on Agenus from $11.00 to $8.00 in a research note on Thursday, March 3rd. One analyst has rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Agenus presently has an average rating of “Hold” and an average price target of $8.75.

Several institutional investors and hedge funds have recently modified their holdings of AGEN. Advisor Group Holdings Inc. lifted its position in Agenus by 12.7% in the 3rd quarter. Advisor Group Holdings Inc. now owns 29,849 shares of the biotechnology company’s stock valued at $158,000 after acquiring an additional 3,370 shares in the last quarter. Leisure Capital Management lifted its position in shares of Agenus by 39.2% during the 4th quarter. Leisure Capital Management now owns 15,763 shares of the biotechnology company’s stock worth $51,000 after buying an additional 4,438 shares in the last quarter. Nations Financial Group Inc. IA ADV lifted its position in shares of Agenus by 42.8% during the 4th quarter. Nations Financial Group Inc. IA ADV now owns 15,016 shares of the biotechnology company’s stock worth $48,000 after buying an additional 4,500 shares in the last quarter. Arizona State Retirement System lifted its position in shares of Agenus by 10.3% during the 3rd quarter. Arizona State Retirement System now owns 48,473 shares of the biotechnology company’s stock worth $254,000 after buying an additional 4,538 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Agenus by 4.4% during the 4th quarter. The Manufacturers Life Insurance Company now owns 110,091 shares of the biotechnology company’s stock worth $354,000 after buying an additional 4,679 shares in the last quarter. Institutional investors own 65.88% of the company’s stock.

Shares of AGEN traded up $0.04 on Thursday, hitting $1.55. The company’s stock had a trading volume of 8,782,729 shares, compared to its average volume of 4,253,182. The company has a quick ratio of 2.12, a current ratio of 2.12 and a debt-to-equity ratio of 0.27. The firm’s fifty day moving average price is $2.41 and its 200-day moving average price is $2.91. Agenus has a fifty-two week low of $1.48 and a fifty-two week high of $6.79. The firm has a market capitalization of $418.92 million, a price-to-earnings ratio of -8.61 and a beta of 1.26.

About Agenus (Get Rating)

Agenus Inc, a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.

Featured Stories